Market & Patient Access

GUEST EDITOR

TBA

Recent product approvals have only increased the sense of urgency to find viable pricing and reimbursement models for cell & gene therapies. They have also brought into sharper focus the need to educate and work with a wide variety of healthcare sector stakeholders – and of course, patients themselves - to ensure society benefits fully from such novel, disruptive therapeutic technologies.

  • Evaluating the suitability of evolving P+R models
  • Dissecting the market and patient access approaches of cell & gene therapy sector leaders
  • Multiple stakeholder engagement strategies